| 16.65 0 (0%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.91 | 1-year : | 24.42 |
| Resists | First : | 17.9 | Second : | 20.91 |
| Pivot price | 14.98  |
|||
| Supports | First : | 15.62 | Second : | 14.21 |
| MAs | MA(5) : | 15.76 |
MA(20) : | 14.86 |
| MA(100) : | 14.72 |
MA(250) : | 13.85 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 66.1 |
D(3) : | 50 |
| RSI | RSI(14): 77.3 | |||
| 52-week | High : | 17.9 | Low : | 11.99 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SWKH ] has closed below upper band by 0.8%. Bollinger Bands are 278.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 16.71 - 16.79 | 16.79 - 16.86 |
| Low: | 16.12 - 16.21 | 16.21 - 16.29 |
| Close: | 16.51 - 16.65 | 16.65 - 16.78 |
SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Further, it intends to out-license its internal product pipeline to create novel formulations using its proprietary technology to develop treatments for patients and caregivers. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.
Fri, 10 Oct 2025
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of SWK Holdings Corporation (SWKH) - TradingView
Fri, 10 Oct 2025
Why Is SWK Holdings Stock Skyrocketing Friday? - SWK Holdings (NASDAQ:SWKH) - Benzinga
Fri, 10 Oct 2025
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An - GlobeNewswire
Thu, 09 Oct 2025
Silicon Valley - FinancialContent
Thu, 09 Oct 2025
SWKH STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of SWK Holdings Corporation Is Fair to Shareholders - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 12 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 6.4 (%) |
| Held by Institutions | 87.3 (%) |
| Shares Short | 49 (K) |
| Shares Short P.Month | 46 (K) |
| EPS | 1.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.22 |
| Profit Margin | 46.5 % |
| Operating Margin | 56.8 % |
| Return on Assets (ttm) | 5.7 % |
| Return on Equity (ttm) | 6.5 % |
| Qtrly Rev. Growth | 44.4 % |
| Gross Profit (p.s.) | 2.86 |
| Sales Per Share | 3.07 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 29 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 11.8 |
| PEG Ratio | 0 |
| Price to Book value | 0.82 |
| Price to Sales | 5.4 |
| Price to Cash Flow | 6.9 |
| Dividend | 4 |
| Forward Dividend | 0 |
| Dividend Yield | 24% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|